Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by mstrmndon Aug 03, 2021 2:48pm
288 Views
Post# 33643073

RE:RE:Screening Failure - Alcohol Until Proven Otherwise

RE:RE:Screening Failure - Alcohol Until Proven OtherwiseCorrect

I'm assuming chronic liver diseases were excluded in all study participants (especially given past issue), therefore, increase in liver enzymes should not be secondary to an acute on chronic process, but rather an acute process

Well what's the differential diagnosis for acute liver enzyme elevation (transaminitis) in the 5x ULN range? 

It's NOT otenaproxesul at 100 mg (because we have strong data readouts at 150 mg, 200 mg, and 250 mg already that proves against this)...renal accumulation because of 21 vs. 14 days is very unlikely...

Therefore, it is alcohol until proven otherwise (other substances or infectious transaminitis less so)...

WalkOverTheStrt wrote: If memory serves a previous study had issues b/c a patient lied about their liver - believe had Hep B or some other disease. Im not on the conspiracy side but more likely a result of drinking, disease that wasnt mentioned, etc.


<< Previous
Bullboard Posts
Next >>